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For the first time the acute interstitial pneumonitis as a main cause of adult idiopathic respira-
tory distress syndrome was described in 1933–35 by the American medical scholars Louis Virgil 
Hamman and Arnold Rice Rich as “acute fibrosing alveolitis” later given the eponymous name 
Hamman-Rich syndrome. This disease targets the interstitium of the lungs and characterized by 
fulminant onset, acute respiratory disorder with possibility of respiratory failure, being clinically 
similar to respiratory distress syndrome with the pathomorphologically revealed diffuse alveo-
lar damage. Hamman-Rich syndrome is characterized by rapid progression from symptoms of 
common cold such as cough, fever, chills and dyspnea to severe respiratory failure. The syn-
drome affects apparently healthy individuals and is not associated with any anamnestic chronic 
lung diseases, smoking habits, neither with patients’ age or sex. The aetiology and pathogenesis 
of the Hamman-Rich syndrome are not clear yet. The familiar genetic predisposition is of defi-
nite meaning, especially related to mutations of surfactant proteins and their metabolism. The 
possible mechanistic links of this fulminant lung disease involve: NK-cells, auto-aggressive im-
mune activation and certain types of cytokines during their excessive systemic action, so-called 
cytokine storm (e.g. interleukin-18 and interleukin-2), which play the leading part in the patho-
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genesis of acute lung cell injury resulting in diffuse non-remitting pneumofibrosis. But all these 
clinical and pathogenetic features are also common for severe COVID-19. Computed tomogra-
phy is used for instrumental diagnosis of Hamman-Rich syndrome and also gives the lung im-
ages quite similar to that of COVID-19, including ground glass opacity symptoms. The authors 
hypothesize that the same link(s) of pathogenesis underlie the severe course of COVID-19 and 
Hamman-Rich syndrome. It is possible that cases of Hamman-Rich syndrome were due to the 
circulation in populations of a less virulent, unrecognized coronavirus, which interacts with the 
immune system of genetically susceptible individuals in a way similar to SARS-CoV2. For sure, 
the identification of the characteristics of the genome of patients with Hamman-Rich syndrome 
will shed light on the genetic mechanisms that predispose to the severe course of COVID-19 
and vice versa — the experience of severe COVID-19 treatment can be applied to the therapy of 
Hamman-Rich syndrome as well.
Keywords: autoimmunity, acute fibrosing alveolitis, acute interstitial pneumonia, COVID-19, 
Hamman-Rich syndrome, acute respiratory distress syndrome, cytokine storm, complement 
C3, interleukin-18, macrophages, natural killers, surfactant proteins. 
Introduction
For the first time the atypical respiratory disease caused by SARS-CoV-2 
(COVID-19) was diagnosed in Wuhan, People’s Republic of China, in December, 2019. 
The virus is highly contagious. It was noticed that the lung involvement caused by COV-
ID-19 in the elderly people has more severe course compared to the children and adoles-
cents. The problem #1 in the world is a need in targeted therapy for the acute interstitial 
pneumonitis and acute respiratory distress syndrome — a dangerous complication of the 
upper respiratory tract disease triggered by COVID-19 [1]. Severe COVID-19 provokes 
an inconsistency of anti-viral immune defense, hyperactivation of macrophages, exces-
sive systemic action of inflammatory autacoids, including cytokines (known under im-
precise term of “cytokine storm”), systemic endothelial involvement with thrombophilic 
syndrome and disseminated intravascular coagulation — all together resulting in a variant 
of shock lung or acute respiratory distress syndrome with fulminant progressing of acute 
respiratory failure [2]. Also, there are clear evidences for autoimmune links taking part in 
pathogenesis of severe COVID-19 [3].
But, maybe some aspects of new coronavirus infection COVID-19 have to be inter-
preted as an old wine in new wineskins?
History of Hamman-Rich syndrome: 
Different meanings of the same term
For the first time the acute interstitial pneumonitis as a main cause of idiopathic 
acute respiratory distress syndrome in adults was described much earlier. In 1933–35 two 
American medical scholars: an internist Louis Virgil Hamman (1877–1946) and a pa-
thologist Arnold Rice Rich (1893–1968) described an idiopathic syndrome. A bit later 
in 1944 they detailed the description with few additional cases — 4 of them in total (see: 
Conclusion below). These publications subsequently gave birth to the eponymous name: 
Hamman-Rich syndrome [4].
The disease targets the interstitium of the lung and is characterized by fulminant 
onset, sometimes with a prodromal period of few days, with non-specific complaints de-
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rived from acute phase response, later manifested in acute respiratory insufficiency with 
the possibility of gravid respiratory failure, clinically similar to acute respiratory distress 
syndrome with diffuse alveolar damage, according to the histopathological results of the 
biopsies [5; 6].
At the beginning the term “Hamman-Rich syndrome” was broadly and incorrectly 
applied to define all forms of diffuse idiopathic pulmonary fibrosis. The term “acute in-
terstitial pneumonia” was introduced by Katzenstein et al in 1968 to define all of the cases 
which resemble true Hamman-Rich syndrome with the purpose to underline that the syn-
drome is an acute idiopathic interstitial lung disease, that differs from interstitial subacute 
and chronic lung diseases based on pathohistological and clinical findings [7; 8]. 
The aetiology, pathogenesis, and factors leading to progressive pneumofibrosis in this 
syndrome are still unknown. There is a hypothesis that assumes the cascade of events end-
ing up with diffuse alveolar damage that begins with acute lesion and subsequently affects 
endothelial vascular cells as well as alveolar epithelium. Epithelial cell damage generates 
local inflammation and systemic acute phase response, when alveolar macrophages pro-
duce cytokines similar to tumor necrosis factor-alpha, interleukin-1 beta and chemotactic 
factor of monocytes — all intensifying inflammatory response. In the alveoli degenerating 
epithelial cells form hyaline membranes which subsequently serve as a base for inflamma-
tory cells, fibroblasts, and myofibroblasts promoting fibroplasia. This phase is character-
ized by fibroblasts proliferation, connective tissue generation, the process occurs within 
the interstitial space and generates its expansion and decrease of gas diffusion. 
It is also important to mention that acute interstitial pneumonia is not limited to cas-
es that show only organized diffuse alveolar damage, because acute phase and organized 
tissue damage can coexist in the same biopsy. Inflammatory cells, especially neutrophils, 
are very few in majority of cases with no reveal of microorganisms. Diffuse proliferation 
of the fibroblasts distinguishes acute interstitial pneumonia from usual interstitial pneu-
monia, entity where fibrosis is chronologically older with small isles of fibroblasts only [9].
The Hamman-Rich syndrome is characterized by rapid progression from symptoms 
of common cold such as cough (usually non-productive, sometimes with scanty sputum), 
fever, chills and dyspnea, aggravating to disorder of pO2 and pCO2 in blood and severe 
respiratory failure. The rapid progressing of respiratory failure is related to non-ventilato-
ry (aka: “parenchymal”) mechanism of decreased diffusion across alveoli-capillary barrier 
and altered perfusion of microcirculatory bed in lesser circulation. This acute syndrome 
affects apparently healthy individuals and is not associated with prior chronic lung diseas-
es, smoking habits, age or gender [10]. At the same time the progression of the disease is 
not associated with comorbid background such as bronchial asthma and can affect people 
most often aged over 40, with a most typical age of 50–55 [11–13], although adolescent 
and pediatric cases were also described [14–21]. 
Aetiology: Genes and environmental factors mosaic interplay
Since Hamman-Rich syndrome occurs both in children and in adults, and there were 
a lot of familial cases described in populations of various ethnicity, it is considered to 
have a hereditary background, and there is an assumption that the syndrome is a genetic 
disease. It was presumed that Hamman-Rich syndrome is an illness with autosomal domi-
nant inheritance type [14–20]. 
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But the genetic aspects of its aetiology are still far from complete elucidation. Familial 
cases of the disease resembling this syndrome were described previously in few articles in 
several generations of relatives. But it is not clear if any of them could match the current 
definition of Hamman-Rich syndrome as an acute interstitial pneumonia. Most probably 
there is a group of hereditary disorders related to surfactant proteins and their metabo-
lism more or less resembling classical manifestations of Hamman-Rich syndrome, but not 
representing a single entity. 
Several descriptions of interstitial pneumoniae and interstitial pneumofibrosis in 
children and adults, first in twin sisters [22] and later in several members of the same 
family in few generations with acute of subacute manifestations were published. In early 
publications their disorders were interpreted as cases of Hamman-Rich syndrome or fa-
milial fibrocystic pulmonary displasia, or fibrosing interstitial pneumonitis [23–25]. Gen-
erally speaking, the pedigrees witnessed for autosomic dominant trait with incomplete 
penetrance. Retrospective molecular genetic analysis of their biomaterial was performed 
in 2002 by Thomas A. Q. et al. [26]. As a result, they found a heterozygous T-to-A trans-
version at genomic position exon 5 + 128 in the SFTPC gene in chromosome 8p, encoding 
highly hydrophobic surfactant C protein (SP-C), produced via several proteolytic pre-
cursor steps, exclusively by type II alveolocytes. The mutation results in a leu188-to-gln 
(L188Q) substitution in a highly conserved region of the C-terminal domain. This re-
gion is crucial to proper intracellular trafficking/folding of the protein. The phenotype in 
this family was variable, with adults showing signs of usual interstitial pneumonitis and 
children showing signs of cellular nonspecific interstitial pneumonitis. Immunostaining 
showed aberrant subcellular localization of the SP-C precursor protein with probable dis-
order of its transportation [26]. 
Thus, surfactant system function establishing the low oxygen costs of breath and pre-
venting alveoli from collapse on exhale by surface tension decrease could be jeopardized 
in these patients. The mutations of SP-C are most frequent ones predisposing to interstitial 
lung diseases in children, but they may have late manifestation as well. For alveolar epithe-
lium these mutations may result in a cell toxicity, increased endoplasmic reticulum stress, 
inflammation and enhanced apoptosis. The distorted epithelial-mesenchymal transition 
under the influence of paracrine inflammatory autacoids causes later diffuse interstitial 
fibrosis of lungs [27]. 
The remarkable feature of the data on probable genetic origin of Hamman-Rich 
syndrome and all closely related entities, resembling its clinical and pathomorphologi-
cal picture, is the presence of different pathological findings in individuals sharing the 
same mutations. This can witness for pleiotropic manifestations of the same core link(s) 
of pathogenesis. Also, in various cases of disease penetrance of genetic defect depended 
on age (more acute and even fulminant in younger individuals) and on various external 
provoking factors — influenza and other infections, occupational hazards etc. The patho-
morphological data also are age-depending. Nathan N. et al. emphasized that: “ground 
glass opacities intensity and extension were decreasing over time, whereas septal thicken-
ing, subpleural and intraparenchymal cysts, and even honeycombing were appearing and 
increasing with age” [28]. It looks like non-genetic events can render lifelong influence on 
penetrance of genetic defects related to Hamman-Rich-like disorders. 
There have been described cases of acute and subacute interstitial lung disease in 
infants and adults with the pathogenesis mainly connected to molecular targets, other 
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than SP-C. It may be gene, encoding ATP-binding cassette-family A-member 3, which is 
responsible for transportation of surfactant proteins B and C into lamellar bodies (ABCA3 
in chromosome 16, recessive trait); or the NKX homeobox 2 gene, which encodes tran-
scriptional promoter of surfactant proteins C and A as well as ABCA3 in lung and some 
other organs (NKX2–1  in chromosome 14, with dominant trait, responsible for lung-
thyroid-diencephalon syndrome); or finally genes of other surfactant proteins — A (in 
chromosome 10) and B (in chromosome 2, recessive trait). 
Surfactant protein B deficiency which caused fatal respiratory failure in a full-term 
infant was described in 1993 for the first time. Following that a lot of cases of the immedi-
ate respiratory failures in newborns were published, and most of them had fatal evolution 
despite aggressive management. Surfactant protein A defects are mostly manifested in 
adults. 
Pathogenesis of all aforementioned genocopies of surfactant system disorders in-
volves lung primary parenchymal dysfunctions and acute respiratory distress syndrome. 
Among the provoking events there are occupational/environment insults, drugs, radiation 
exposure, rheumatological autoimmune diseases, vasculitides, auto-inflammatory disor-
ders and viral infections [27; 29].
We consider that Hamman-Rich syndrome, at least, is not induced by the bacterial 
aetiological factors, because there is no effect from antibacterial therapy [19], and blood 
concentrations of biomarkers such as ММР-7, CCL18, KL-6, SP-A и SP-D are significally 
different in cases of bacterial pneumoniae and Hamman-Rich syndrome [29].
Viruses took one of the central roles in mechanism of pediatric interstitial lung dis-
eases, as they target alveolar epithelium. Hence, viral provocation considered to be essen-
tial for Hamman-Rich syndrome. Among viral agents most often mentioned in relation 
to Hamman-Rich syndrome are: Adenovirus, Epstein-Barr virus, cytomegalovirus, and 
respiratory syncytial virus. More rarely implicated are: Influenza A, hepatitis C and hu-
man immunodeficiency virus [30–32].
Pathogenesis and manifestations of Hamman-Rich syndrome
The pathogenesis of the Hamman-Rich syndrome is obscure. The following possible 
players in mechanisms underlying this fulminant lung disease are: Natural killer cells and 
excessive action of certain type of cytokines — so-called cytokine storm (especially, medi-
ated via interleukin-18 and interleukin-2). These agents can play the leading part in the 
pathogenesis of the acute cell injury with the resulting no remitting fibrosis, in particular 
through cell injury [31–33]. Other authors suppose that immune complexes play some 
role in pathogenesis as they are commonly involved in many cases of vasculitides [34]. The 
role of autoimmune component in Hamman-Rich syndrome pathogenesis is not rejected, 
because many of the viruses mentioned above as its triggers, are also known to provoke 
autoimmunity (like Epstein-Barr virus, citomegalovirus, and hepatitis C virus [29].
The disease is often preceded by acute upper respiratory tract infection that lasts ap-
proximately 1–2  weeks. The most common symptoms are dyspnea, cough, sub febrile 
temperature and in some cases — high fever. Patients can also suffer from muscle weak-
ness and fibromyalgia. Acute respiratory failure develops in previously healthy patients 
without any chronic lung diseases. The symptoms of acute respiratory failure include 
tachypnea, dyspnea, cyanosis, whistles and wheezing of the lungs on auscultation. Fulmi-
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nant respiratory failure usually affects patients between 50–55 years old equally males and 
females without prior risk factors in anamnesis [35].
The above mentioned initial clinical symptoms of the acute interstitial pneumoni-
tis are caused by acute phase response with prodromal/catarrhal symptoms that progress 
very fast (in several days) to bilateral pneumonia and respiratory insufficiency leading to 
fatal outcome almost in 70 % of cases.
Basically, the patient is feeling like he or she is drowning — previously healthy indi-
vidual without chronic respiratory disease can develop fulminant respiratory insufficiency 
after the initial symptoms of common cold.
Final diagnosis is made based on clinical picture and histopathological studies of 
the patients with acute respiratory failure. In the early stages of diffuse alveolar dam-
age hyaline membranes are determined. As the disease progresses, resorption of hyaline 
membranes occurs, fibroblasts migrate to alveolar septation area and rapidly proliferate, 
causing elevated Ki67 marker expression on immunohistochemistry. In the late stages in-
terstitial fibroblasts consolidation is observed. Characteristic features can include atelecta-
sis, hyperplasia of pneumocytes type 2, edema of interalveolar septum, and micro- throm-
bosis of small pulmonary arteries. Cytology can be described as alveolar macrophages 
and scattered mixed inflammatory cells. Diagnosis is proved by computed tomography of 
high resolution. The main findings of instrumental research methods are bilateral sym-
metric pulmonary infiltration that can be local or diffuse. Spirometry shows restrictive 
pattern with decreased diffusing capacity of the lungs. Laboratory tests are characterized 
by neutropenic leukocytosis, increased creatinine, decreased hematocrit, that is consid-
ered a bad prognostic factor. Bronchoalveolar lavage usually shows neutrophilia with acci-
dental atypical pneumocytes type 2 and extracellular amorphous material that represents 
fragments of hyaline membranes. Lavage study is used to differentiate acute respiratory 
pneumonia from other types of pneumonia. So, for example, absence of eosinophils can 
help to exclude acute eosinophilic pneumonia, absence of lymphocytosis and foam mac-
rophages may exclude cryptogenic pneumonia, and pneumonia caused by medications. 
Biopsy helps to exclude known causes of diffuse alveolocytes’ damage, for instance, such 
as idiopathic lung fibrosis exacerbation [11].
Chest X-ray shows diffuse bilateral lung tissue air opacification that resembles 
ground glass or smoke. High resolution computed tomography (CT) scan of the chest 
shows bilateral symmetrical patches that resemble hyaline opacities. The acute interstitial 
pneumonitis resembles other cases of acute respiratory distress syndrome both clinically 
and instrumentally [36]. The main criteria of the acute respiratory syndrome include: Idi-
opathic acute respiratory distress and histopathological findings consistent with organ-
ized pneumonia. 
The diagnosis of Hamman-Rich syndrome is based on 4 principles: 1) acute onset of 
symptoms which coincide with severe hypoxemia and in majority of cases — respiratory 
failure; 2)  bilateral pulmonary infiltrates evident on radiological images; 3)  absence of 
identified aetiology or predisposing condition; 4) pathohistology report with idiopathic 
diffuse alveolar damage, finding which is not present in any other idiopathic interstitial 
pneumonia. 
To confirm the diagnosis it is essential to perform open thoracoscopic lung biopsy. 
The findings of the biopsy during the exudative phase are characterized by edema, hyaline 
membranes, acute interstitial inflammation, and later, during the organized phase — by 
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organized fibrosis, preferably located between alveolar septae with hyperplasia of type 2 
pneumocytes [5]. 
It is worth to note that Hamman-Rich syndrome is regularly complicated by pulmo-
nary heart disease (cor pulmonale) and heart failure [37].
Still without radical treatment
The treatment of Hamman-Rich syndrome is mostly symptomatic and/or supportive: 
with oxygen therapy and mechanical lung ventilation. It is not clear whether glucocorti-
coid therapy is always effective as a treatment method of the acute interstitial pneumonitis. 
Some specialists came to conclusion that it is necessary to use pulse therapy with maximal 
doses of corticosteroids as the most effective among other methods of conservative treat-
ment [38]. Other immunosuppressing medicines and anti-fibrotic therapy also is used. 
Glucocorticoids in pediatric cases of Hamman-Rich syndrome look more effective (circa 
50 % of recovery), than in elderly patients, mortality rate in children is lower (circa 15 %), 
than in adults [32; 39]. Interestingly, chloroquine was tested for therapy of Hamman-Rich 
syndrome and showed 60 % effectiveness [40].
In adults even the aggressive treatment, which includes mechanical lung ventilation, 
is characterized by a high rate of lethality (more than 60 %), and most patients die during 
the next 6 months after initial hospitalization. But, getting the disease once, patients (if 
they did overcome it) do not get sick again after recuperation and, according to the labo-
ratory and instrumental data, in many cases have considerable recovery of the functional 
lung capacity [41]. 
One research specifies higher numbers of survival where the main role is assigned 
to the early diagnostic approach, protective regimen of lung ventilation and early immu-
nosuppressive therapy usage [5]. One may look many similarities in ways and failures of 
Hamman-Rich and COVID-19 treatment (see below). There is still an open question re-
garding target therapy. Potentially, as a candidate for pathogenetic treatment of Hamman-
Rich syndrome can be regarded anti-cytokine immunobiotherapy (like in COVID-19).
Some cases of Hamman-Rich syndrome in elderly patients are described in medical 
literature as a fulminant form of the interstitial lung disease. Prodromal phenomena precede 
those cases, and in some occasions, there was no response to intensive and even aggres-
sive therapy, including antibacterial therapy, diuretics, glucocorticosteroids, and mechanical 
lung ventilation. Such cases were often fatal in 10–35 days after hospitalization [42]. 
Some authors, stressing the importance of open thoracoscopic lung biopsy in diag-
nosis of Hamman-Rich syndrome, insist on single possible radical approach in its treat-
ment — that is lung transplantation [10].
COVID-19 vs Hamman-Rich syndrome: Close similarities
The discoverer of general adaptation syndrome, Hungarian-Canadian pathophysi-
ologist Hans Hugo Bruno Selye (1907–1982) once noted, that clinicians always try to find 
difference between the diseases, but for a pathologist the most interesting thing is why 
various diseases look so similar. 
In regards to Hamman-Rich syndrome, we shall mention a correlation which seems 
to us quite important. 
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Comparing early and advanced clinical manifestations, lung pathomorphology and 
outcomes, as well as typical sub-acute complications of Hamman-Rich syndrome and fea-
tures of its treatment — with all that facets of severe COVID-19 [43–45], we noticed strik-
ingly close resemblance of these two entities [37].
The most important facet, in our opinion, is that the pathogenesis of the acute inter-
stitial pneumonitis triggered by COVID-19 with its cytokine cascade and acute respira-
tory distress, has many similarities to that of Hamman-Rich syndrome. In most severe 
cases, the course of COVID-19 disease is characterized not only by fever, cough and other 
constitutional symptoms, but also by acute respiratory insufficiency, dyspnea and possi-
ble lethal outcome. Laboratory data will reveal leukopenia, significant liver transaminases 
(hundreds or even thousands) and huge ferritin level rise. These signs define also hyper-
ferritinemic syndrome — macrophage activation syndrome, catastrophic antiphospholip-
id syndrome, septic shock and side effects on the biological component anti-CD-28. Such 
clinical scenario may be universal and can correlate with the syndrome of macrophage ac-
tivation that is associated with high ferritin levels, wich was first coined by Yehuda Shoen-
feld et al. in 2020 [3]. Acute respiratory distress syndrome is the devastating clinical mani-
festation of COVID-19 pneumonia that is mainly based on immune-mediated pathologi-
cal processes. Current studies show that pneumonia cascade in any case, not excluding 
neither old, nor newest aetiologies, is mediated by maladaptive inflammatory responses 
that excessively activate innate immune responses [32–33]. So called cytokine storm was 
detected and documented with the participation of IL-6, IL-2, and IL-18 [3; 43–45]. The 
activation of complement C3 system, as the primary trigger mechanism impairing pulmo-
nary tissue on preclinical models by infection SARS-CoV-2, was described [46].
Indeed, in our opinion the severe COVID-19, with its fever and dry non-productive 
cough and coming later interstitial pneumonia with diffuse alveolar damage and acute 
respiratory distress syndrome, as well as with its outcome to diffuse interstitial pneumofi-
brosis — looks in all above said features — very much like acquired “phenocopy” of Ham-
man-Rich syndrome, although latter apparently never was considered to be a contagious 
disease. 
Either sporadic cases of Hamman-Rich syndrome were related to unrecognized 
type of coronavirus having small contagiousness. Or, which looks much more probable, 
both entities, having different (infectious and non-infectious, presumably, genetic) aeti-
ologies, address in their pathogenesis to similar or identical weak point(s) of immune sys-
tem, making its auto-inflammatory and auto-aggressive potential the key player in both 
entities.
Anyway, it seems to us quite possible that Hamman-Rich syndrome under closer 
look may contain a key for comprehension of the COVID-19. There was even an obser-
vation that pneumofibrosis in survivors of Hamman-Rich syndrome can exacerbate into 
acute respiratory distress syndrome due to viral and even coronavirus infection, although 
last was reported only in one of 43  cases of such exacerbation [47; 48]. To study pre-
cisely and compare the genetic and immunological features of those people having severe 
COVID-19 and those suffered from Hamman-Rich syndrome may offer a fruitful ap-
proach for prognostic purposes and pathogenetically based intervention [37].
Inherited epigenetic dysregulations of the immune system can be the portals of entry 
for infection, thus contributing to viremia and launching of excessive immune response 
to SARS-CoV-2 [49] or other still unknown Hamman-Rich syndrome provoking agent(s).
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In regards to probable common targets of pathological processes in both COVID-19 
and Hamman-Rich syndrome, one has to think about involvement of the surfactant system. 
We already cited a comprehensive international study which demonstrated the exist-
ence of autoimmune links in pathogenesis of COVID-19, with lymphoid infiltration of lungs 
and other organs and provocation of different autoimmune diseases by COVID-19 [3].
But, the Hamman-Rich syndrome also was linked to some autoimmune conditions. 
Frequent comorbidity of this syndrome and autoimmune rheumatological diseases has 
been described. Up to 40 % of cases in some samplings were positive for antinuclear au-
toantibodies or rheumatoid factors [38; 50; 51]. Interstitial fibrosing alveolitis overlap-
ping with manifestations of Hamman-Rich syndrome can be observed in children and 
adults affected with several autoimmunopathies: Rheumatoid arthritis, systemic sclerosis, 
systemic lupus erythematosus, Sjőgren syndrome, dermatomyositis and polymyositis, an-
kylosing spondylitis, and mixed connective tissue disease, as well as in autoimmune vas-
culitides and anti-synthetase syndrome [28; 52]. Some autoantibodies, like anti-Ro52 and 
anti-Ku correlated with dyspnea and other symptoms in patients with interstitial lung 
diseases, including acute ones [52]. 
There is a common general rule in Pathophysiology, that similar disorders may be 
brought in by either genetic defect of certain protein, or equally  — by autoantibodies 
against this protein, spoiling its function and/or assembly with other proteins, even with-
out its primary genetic defects. This can be illustrated by the examples of similarities 
between primary inherited or secondary autoimmune cardiomyopathies, or by the case 
of inherited blistering mechanodermatoses versus acquired immunodermatoses, which 
clinically closely resemble them[53; 54].
We hypothesize, that similar parallelism may exist between Hamman-Rich syndrome 
and COVID-19.
As it was mentioned above, hereditary defects of surfactant proteins (SP-C and oth-
ers) and molecules involved in their transportation and metabolism are of utmost signifi-
cance for the genetic background of Hamman-Rich syndrome and those forms of pathol-
ogy closely related to it. For example, there are cases of idiopathic pulmonary fibrosis that 
are caused by heterozygous mutation in the SFTPA2 gene (178642). This gene encodes 
pulmonary surfactant protein A2 on chromosome 10q22 [55]. 
D. Kanduc and Y. Shoenfeld suggested recently that because the SARS-CoV-2 spike 
glycoprotein and lung surfactant proteins shared 13 out of 24 pentapeptides, the immune 
response following infection with SARS-CoV-2 may lead to cross-reactions with pulmo-
nary surfactant proteins, followed by SARS-CoV-2-associated lung disease. Later A. Vo-
jdani et al have broaden these studies [56; 57].
Human vs SARS-CoV-2  peptide sharing is of high relevance with 13  out of the 
24 shared pentapeptides to be found in 52 SARS-CoV-derived immunoreactive epitopes. 
Given the caveat that the positive correlation of the pentapeptide sharing needs to be 
controlled by serologic validation, results suggest that immune responses following SARS-
CoV-2 infection might lead to cross reactions with pulmonary surfactant and related pro-
teins, and might contribute to the SARS-CoV-2-associated lung diseases [56].
Looking at the reaction between SARS-CoV-2 spike protein antibody and other tis-
sue proteins the strongest reactions were found with transglutaminase 3 (tTG3), trans-
glutaminase 2 (tTG2), ENA, myelin basic protein (MBP), mitochondria, nuclear antigen 
(NA), α- myosin, thyroid peroxidase (TPO), collagen, claudin 5+6, and S100B [57].
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There is a possibility that SARS-CoV-2 infection through autoantibodies induction 
may damages the same peptides of surfactant proteins that are defective in a hereditary 
form of idiopathic fibrosing alveolitis cases close to Hamman-Rich syndrome. 
There are many similarities in ways of treatment for Hamman-Rich syndrome (see 
above) and severe COVID-19 because acute respiratory distress syndrome occurs in both 
diseases. Exactly like in Hamman-Rich syndrome, in COVID-19 also there are reports of 
successful use of corticosteroids, but despite intensive treatment with glucocorticosteroids 
the lethal cases are not rare [58]. The alternative immunosuppressive medications (chlo-
roquine, vincristine, cyclophosphamide, cyclosporin, and azathioprine) and lung trans-
plantation have also been presented in some pilot projects as possible treatment methods, 
although with limited efficacy [59].
Hamman-Rich syndrome and COVID-19: Hard differential diagnosis
The similarity between Hamman-Rich syndrome and COVID-19 is not only just the-
oretical consideration coined by pathologists. It already created some practical hardships 
in differential diagnosis during current COVID-19 pandemic.
Thus, Jennifer Obasi describes a case of previously healthy 64 years old female who 
presented with symptoms of acute dyspnea, fever, unproductive cough, arthralgias and 
myalgias and despite aggressive treatment with high-dose corticosteroids, mechanical 
ventilation, continued to experience refractory hypoxia and subsequently passed away. 
She was COVID-19 negative, did not have any chronic lung disease. The patients autopsy 
confirmed findings characteristic for diffuse alveolar damage: interstitial edema with al-
veolar septae thickening, inflammatory cell infiltration, hyaline membranes alongside of 
the alveolar septa in focal areas and thrombi in small pulmonary arteries. A diagnosis of 
acute interstitial pneumonia (Hamman-Rich syndrome) was made [60]. 
The differential diagnosis between Hamman-Rich syndrome and acute interstitial 
pneumonia triggered by COVID-19 is challenging because the clinical presentation is 
similar  — prodromal illness lasts 7–14  days prior to rapid onset of respiratory failure, 
fever, nonproductive cough, fatigue. Radiological findings are the same: patients with con-
firmed COVID-19 had extensive ground-glass opacities on CT-scans, as well as patients 
with negative COVID-19 tests and acute interstitial pneumonias. Atypical presentation 
of COVID-19 disease can also be taken into consideration while interpreting clinical and 
radiological findings. A case of differential diagnosis between COVID-19 and Hamman-
Rich syndrome in a 77 years old female Chinese patient was reported just recently [61]. 
The bronchoscopy with lung biopsy can be useful while making a diagnosis of Hamman-
Rich syndrome. An interesting case of incidental tracheal bronchus found during bron-
choscopy in a patient with Hamman-Rich syndrome was described by Luca Conti [62]. 
The role of bronchoscopy is to eliminate other possible diagnoses such as alveolar hem-
orrhage, eosinophilic infiltrates, or lymphoma /cancer infiltrates. Bronchoalveolar lavage 
can show in Hamman-Rich syndrome presence of neutrophils, atypical epithelial cells, 
however those findings are not specific, that is why open or video guided lung biopsy can 
be beneficial [9]. Alongside acute respiratory distress syndrome, there are 3 types of inter-
stitial pneumoniae that should be excluded: Usual interstitial pneumonia, desquamous in-
terstitial pneumonia and cryptogenic organized pneumonia. The main difference is based 
on disease duration. Acute interstitial pneumonia (equivalent of classic Hamman-Rich 
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syndrome) takes its fulminant course, whereas desquamous pneumonia, in addition to 
tobacco smoking association, has subacute course of weeks and months, and usual pneu-
monia lasts during years. Cryptogenic pneumonias, although acute, respond excellently to 
systemic corticosteroid treatment and have excellent clinical prognosis. 
Conclusion
History of Pathology is not just a dead dusty book from a remote shelf of rarely visited 
library store. Sometimes it may teach contemporary physicians helping to comprehend 
diseases which seem to be new, and in these cases a disease “out of fashion” gives much for 
better understanding of a “disease in fashion”. The incidence and epidemiological dynam-
ics of COVID-19 is followed daily by everyone, even those observers standing beyond 
professional medical community. But the epidemiology of Hamman-Rich syndrome and 
related idiopatic fibrosing interstitial lung diseases for a long time was out of scope of 
scholarly attention. We were able to retrieve only one such study of mid–1990ies, docu-
menting the increase in its mortality rate, especially in Britain, as well as the prevail of 
male patients in all countries studied [63]. 
But, an old discovery by L. V. Hamman and L. R. Rich [64–66] definitely has a big 
chance to come in fashion again with the progress of COVID-19 pandemic. 
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